
Asher Bio
Asher Bio is a YC Summer 2019 (S19) company. Based in San Carlos, CA, USA. Team of 3.
About Asher Bio
Summary
Asher Bio develops cis-targeted immunotherapies for cancer, autoimmune, and infectious diseases. Its platform works by engaging two molecules on the same immune cell, an immunomodulatory receptor and a cell-type-specific target, so that only the desired immune cells are activated. This approach replaces conventional immunotherapies that act broadly across multiple cell types, causing off-target toxicity and reduced efficacy.
Go-to-market
Asher Bio advances its therapies through clinical trials, with its lead molecule etakafusp alfa currently in a Phase 1a/1b trial, targeting patients with cancer via a drug-development pipeline aimed at eventual partnering or commercialization.
From the Y Combinator listing
We build better immunotherapies
Asher Bio is a biotechnology company developing precisely targeted immunotherapies for cancer and other diseases. Our cis-targeting platform aims to enable selective activation of specific immune cell types, addressing the inherent limitations of otherwise pleiotropic immunotherapies that act on multiple cell types. Our approach has the potential to precisely direct different immune mediators against a range of target immune cell-types and create best-in-class immunotherapies in cancer, autoimmune and infectious diseases. Asher Bio is backed by Third Rock Ventures and is located in South San Francisco.
Facts
- Healthcare / Healthcare -> Therapeutics
- San Carlos, CA, USA
- 3
- Active
- Growth
Founders (2)
- Andy Yeung
- Ivana Djuretic
Score every batch against your own thesis
GPAgent's sourcing agent reads every company in a batch, scores each one against your fund's thesis in a private workspace, and lines up the founders worth meeting before Demo Day. You decide who to contact. Your scores, notes, and pipeline never appear on these pages.
How Accelerator intelligence works